{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:57:13Z","timestamp":1779217033217,"version":"3.51.4"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Concurrent development of therapy\u2212related acute myeloid leukemia (t\u2212AML) and lymph node tuberculosis (LNTB) following comprehensive anti\u2212tumor therapy for locally advanced lung squamous cell carcinoma (LSCC) is extremely rare in clinical practice. This is not a new biological concept but represents a rarely documented clinical scenario in the setting of neoadjuvant chemoimmunotherapy, surgery, and anti\u2013PD\u22121 maintenance therapy. Herein, we systematically summarize the clinical features, pathogenesis and individualized therapeutic strategies of these two concurrent rare complications based on a single rare case and the latest relevant literature, to provide a reference for clinical diagnosis and treatment. A 54-year-old male patient was initially diagnosed with locally advanced LSCC. After four cycles of neoadjuvant therapy with carboplatin, albumin-bound paclitaxel and pembrolizumab, the tumor lesion regressed markedly. Thoracoscopic right upper lobectomy was then performed, followed by maintenance immunotherapy with single-agent pembrolizumab postoperatively. Four months after maintenance therapy, the patient developed abnormalities on routine blood work, low-grade fever, fatigue and superficial lymphadenopathy. t-AML was confirmed by bone marrow aspiration, immunophenotyping, gene mutation and cytogenetic examinations, accompanied by breast cancer susceptibility gene 2 (\n                    <jats:italic>BRCA2<\/jats:italic>\n                    ), DNA (cytosine-5)-methyltransferase 3 alpha (\n                    <jats:italic>DNMT3A<\/jats:italic>\n                    ), and isocitrate dehydrogenase 2 (\n                    <jats:italic>IDH2<\/jats:italic>\n                    ) mutations, and positivity for lysine (K)-specific methyltransferase 2A partial tandem duplication (\n                    <jats:italic>KMT2A-PTD<\/jats:italic>\n                    ). Meanwhile, LNTB was diagnosed by lymph node aspiration pathology combined with tuberculosis-specific assays. The patient was treated with an optimized quadruple anti-tuberculosis regimen (HZEM), and induction chemotherapy for AML with VA regimen (venetoclax plus azacitidine) plus revumenib, and supportive therapy. Subsequently, the patient achieved partial remission of leukemia, with no uncontrollable severe adverse events. In this case, LSCC was managed with neoadjuvant therapy, thoracoscopic right upper lobectomy and postoperative maintenance therapy with single agent pembrolizumab. The development of t\u2212AML is primarily driven by cytotoxic DNA damage induced by chemotherapeutic agents, whereas the potential contribution of immune checkpoint inhibitors remains largely speculative. The potential contribution of immune checkpoint inhibitors via immune microenvironmental disturbance remains largely speculative and insufficiently documented by current clinical evidence. The impaired immune function caused by comprehensive anti-tumor therapy may further elevate the risk of LNTB. The overlapping clinical manifestations of the two concurrent diseases substantially increase diagnostic difficulty. Timely and thorough bone marrow examination, lymph node pathological biopsy and tuberculosis-specific screening are the keys to early and accurate diagnosis.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1820207","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:41:30Z","timestamp":1776228090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Concurrent therapy-related acute myeloid leukemia and lymph node tuberculosis following treatment for lung squamous cell carcinoma: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Yonglin","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Nursing, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoju","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Sichuan Friendship Hospital","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, China"]},{"name":"The First Clinical Medical College, General Hospital of Ningxia Medical University","place":["Ningxia, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.09.018","article-title":"Squamous cell lung cancer: current landscape and future therapeutic options","volume":"40","author":"Lau","year":"2022","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2025.11.008","article-title":"Emerging options and future strategies in immunotherapy for advanced lung squamous-cell carcinoma","volume":"37","author":"Wang","year":"2026","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100444","article-title":"First-line pembrolizumab plus chemotherapy for advanced squamous NSCLC: real-world outcomes at U.S. oncology practices","volume":"4","author":"Liu","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1590017","article-title":"The benefits and risks of adding PD-1\/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials","volume":"15","author":"Xu","year":"2025","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1186\/s12885-020-07603-9","article-title":"Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6322","article-title":"Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France","volume":"12","author":"Belhabri","year":"2023","journal-title":"Cancer Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281233","article-title":"Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications","volume":"108","author":"Nilsson","year":"2023","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-024-2974-3","article-title":"The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China","volume":"69","author":"Tang","year":"2026","journal-title":"Sci China Life Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2023.01.026","article-title":"The prevalence, risk factors, and public health consequences of peripheral lymph node-associated clinical and subclinical pulmonary tuberculosis","volume":"129","author":"Heffernan","year":"2023","journal-title":"Int J Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1186\/s12879-024-09511-w","article-title":"Efficacy and tolerability of a 4-month ofloxacin-containing regimen compared to a 6-month regimen in the treatment of patients with superficial lymph node tuberculosis: a randomized trial","volume":"24","author":"Hissar","year":"2024","journal-title":"BMC Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2021.12.013","article-title":"Immunosuppressive features of the microenvironment in lymph nodes granulomas from tuberculosis and HIV-co-infected patients","volume":"192","author":"Ashenafi","year":"2022","journal-title":"Am J Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004440","article-title":"Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer","volume":"10","author":"Lopez de Rodas","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-003-0416-0","article-title":"Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer","volume":"388","author":"Li","year":"2003","journal-title":"Langenbecks Arch Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.727220","article-title":"Increased tuberculosis incidence due to immunotherapy based on PD-1 and PD-L1 blockade: a systematic review and meta-analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s40425-019-0717-7","article-title":"Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations","volume":"7","author":"Anastasopoulou","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1700157","DOI":"10.1183\/13993003.00157-2017","article-title":"Risk of tuberculosis in patients with solid cancers and haematological Malignancies: a systematic review and meta-analysis","volume":"50","author":"Dobler","year":"2017","journal-title":"Eur Respir J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1344821","article-title":"Progress in mechanism-based diagnosis and treatment of tuberculosis comorbid with tumor","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-017-0875-z","article-title":"Analysis of clinical profile and outcome of tuberculosis in patients with acute leukemia","volume":"34","author":"Jain","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s10238-025-01795-9","article-title":"The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies","volume":"25","author":"Soleimani Samarkhazan","year":"2025","journal-title":"Clin Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1180757","article-title":"A case report of complete remission of acute myeloid leukemia combined with DNMT3A, FLT3-TKD, and IDH2 gene mutations\u00a0and active pulmonary tuberculosis treated with homeharringtonine + venetoclax + azacytidine","volume":"10","author":"Ji","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2017.11.004","article-title":"Evaluation of coexistence of cancer and active tuberculosis; 16 case series","volume":"23","author":"\u00c7akar","year":"2018","journal-title":"Respir Med Case Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1038\/s41467-024-50384-z","article-title":"Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms","volume":"15","author":"Bertrums","year":"2024","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0328","article-title":"Mutagenic impact and evolutionary influence of chemoradiotherapy in hematologic\u00a0Malignancies","volume":"6","author":"Diamond","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.105853","article-title":"Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors","volume":"161","author":"Im","year":"2020","journal-title":"Respir Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061658","article-title":"Progress toward better treatment of therapy-related AML","volume":"15","author":"Kotsiafti","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/life14030309","article-title":"Recent advances towards the understanding of secondary acute myeloid leukemia progression","volume":"14","author":"Auerbach","year":"2024","journal-title":"Life (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1736554","article-title":"The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer","volume":"19","author":"Mazarico Gallego","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v8.i13.2833","article-title":"Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: a case report","volume":"8","author":"Kim","year":"2020","journal-title":"World J Clin cases"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by\u00a0anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from\u00a0myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05803-y","article-title":"The role of clonal progression leading to the development of therapy-related myeloid neoplasms","volume":"103","author":"Guarnera","year":"2024","journal-title":"Ann Hematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004668","article-title":"Mutational patterns and their correlation to CHIP-related mutations and age in hematological Malignancies","volume":"5","author":"Stengel","year":"2021","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281580","article-title":"Germline loss-of-function BRCA1 and BRCA2 mutations and risk of de novo hematopoietic Malignancies","volume":"109","author":"Stubbins","year":"2024","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-5","article-title":"Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients","volume":"5","author":"Chotirat","year":"2012","journal-title":"J Hematol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244171","article-title":"Unveiling the complexity of KMT2A rearrangements in acute myeloid leukemias with optical genome mapping","volume":"16","author":"Lacoste","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41389-020-0191-6","article-title":"DNMT3A mutants provide proliferating advantage with augmentation of self-renewal activity in the pathogenesis of AML in KMT2A-PTD-positive leukemic cells","volume":"9","author":"Bera","year":"2020","journal-title":"Oncogenesis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-350","article-title":"Decoding the tumor immune microenvironment in lung squamous cell carcinoma: characteristics, regulatory mechanisms, and future directions in immunotherapy","volume":"14","author":"Tong","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.09.072","article-title":"Tuberculosis treatment incompletion in patients with lung cancer: occurrence and predictors","volume":"113","author":"Lee","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2013.12.020","article-title":"Clinical research progress of hematological Malignancies complicated with active tuberculosis","volume":"34","author":"Li","year":"2013","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cells13060504","article-title":"Implementing whole genome sequencing (WGS) in clinical practice: advantages, challenges, and future perspectives","volume":"13","author":"Brlek","year":"2024","journal-title":"Cells"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2024.110842","article-title":"Advancements in long-read genome sequencing technologies and algorithms","volume":"116","author":"Espinosa","year":"2024","journal-title":"Genomics"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.3608","article-title":"Guidelines for next-generation sequencing in sarcoma diagnosis and treatment: a consensus review","volume":"11","author":"Serrano","year":"2025","journal-title":"JAMA Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0103","article-title":"Therapy-related myeloid neoplasms: complex interactions among cytotoxic therapies, genetic factors, and aberrant microenvironment","volume":"5","author":"Singhal","year":"2024","journal-title":"Blood Cancer Discov"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1820207\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:41:50Z","timestamp":1776228110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1820207\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":50,"alternative-id":["10.3389\/fonc.2026.1820207"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1820207","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1820207"}}